After living with metastatic breast cancer for 11 years, I reflect on my journey and plan to embrace the coming year with ...

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

Patients diagnosed with more advanced breast cancer are more likely to have cardiovascular disease, a large study suggests.

SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Oppenheimer 35 th Annual Healthcare Life Sciences Conference: Zymeworks' management will participate in virtual one-on-one ...

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked up from Xencor. | Roche has given two early-phase bispecifics the heave-ho ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...